Table 2.
Residues interacting with WIN compounds
| Position | HRV14 and HRV3 | HRV16 | HRV1A | |
|---|---|---|---|---|
| Ala-1150 | Tyr-1142 | Tyr-1145 | ||
| Pro-1174 | Ala-1166 | Met-1169 | ||
| Toe | Val-1176 | Val-1168 | Ile-1171 | |
| Leu-3014 | Met-3014 | Met-3014 | ||
| Ala-3024 | Ala-3024 | Ala-3024 | ||
| Ile-1130 | Met-1124 | Leu-1127 | ||
| Met-1224 | Leu-1217 | Ile-1220 | ||
| Phe-1186 | Phe-1179 | Phe-1182 | ||
| Val-1188 | Leu-1181 | Ile-1184 | ||
| Tyr-1152 | Tyr-1144 | Tyr-1147 | ||
| Val-1243 | Ile-1236 | Ile-1239 | ||
| Val-1077 | Ile-1077 | Val-1077 | ||
| Middle | Trp-1102 | Trp-1096 | Trp-1099 | |
| Ile-1104 | Ile-1098 | Ile-1098 | ||
| Tyr-1128 | Ile-1122 | Ile-1125 | ||
| Val-1191 | Leu-1184 | Leu-1187 | ||
| Met-1221 | Met-1214 | Met-1217 | ||
| Leu-1106 | Leu-1100 | Leu-1103 | ||
| Heel | Tyr-1197 | Tyr-1190 | Tyr-1193 | |
| Asn-1219 | Asn-1212 | Asn-1215 | ||
| Phe-1124 | Phe-1118 | Phe-1121 |
The residue(s) in bold are the most bulky residue in this position. The residues in italics are conserved between the serotypes in this position.